Iron Status, Erythropoietin, and Cancer Incidence in the General Population
Open Access
- 8 May 2026
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 56 (5) , e70218
Abstract
Background: Iron is essential for cellular function and cancer growth. While iron imbalance has been implicated in cancer development, epidemiological evidence remains inconsistent. Erythropoietin (EPO) may influence tumour progression. We aimed to investigate the associations between iron status, EPO levels, and cancer incidence in the general population. Method: Data were obtained from 6109 participants (mean age 52 ± 12 years; 49% male) in the Prevention of Renal and Vascular End‐stage Disease (PREVEND) cohort. Iron biomarkers, including ferritin, transferrin saturation, soluble transferrin receptor (sTfR), hepcidin and EPO levels, were measured at baseline. Results: Over a median 18.5 year follow‐up, 1090 participants developed cancer. Multivariable Cox regression revealed that higher EPO (HR 1.26; 95% CI 1.07–1.47; p = 0.005) was associated with increased overall cancer risk, while elevated hepcidin levels were associated with a lower risk (HR 0.88; 95% CI 0.80–0.96; p = 0.006). Higher sTfR (HR 1.35; 95% CI 1.01–1.80; p = 0.043) was suggestive for an increased risk of overall cancer. After excluding early diagnoses, the increased risk associated with higher EPO levels and decreased risk associated with higher hepcidin levels remained significant. Lower transferrin saturation was associated with increased haematological cancer risk, while higher hepcidin was associated with reduced gastrointestinal cancer risk, especially in women and those with BMI < 25 kg/m 2 . In non‐smokers, higher sTfR and EPO were associated with increased overall and kidney cancer. Conclusion: These findings underscore the putative roles of iron metabolism and EPO in cancer, with consistently decreased risks associated with elevated hepcidin levels, particularly among women and individuals with lower BMI.Keywords
Funding Information
- Nierstichting (E.033)
- Hartstichting (2001.005)
- Ministerie van Volksgezondheid, Welzijn en Sport
- National Institutes of Health
- Universitair Medisch Centrum Groningen
This publication has 27 references indexed in Scilit:
- Risk of Cancer in Patients with Iron Deficiency Anemia: A Nationwide Population-Based StudyPLOS ONE, 2015
- Erythropoietin and Cancer: The Unintended Consequences of Anemia CorrectionFrontiers in Immunology, 2014
- The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesisBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013
- Manipulation of the hepcidin pathway for therapeutic purposesHaematologica, 2013
- Erythropoietin in cancer: a dilemma in risk therapyTrends in Endocrinology & Metabolism, 2013
- Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjectsEuropean Journal of Medical Research, 2010
- The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cellsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and ArchiveAnalytical Cellular Pathology, 2007
- Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its InternalizationScience, 2004
- Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidityJournal of Internal Medicine, 2001